Open AccessToward “off‐the‐shelf” allogeneic CAR T cells
Author(s) -
Aftab Blake T.,
Sasu Barbra,
Krishnamurthy Janani,
Gschweng Eric,
Alcazer Vincent,
Depil Stéphane
Publication year - 2020
Publication title -
advances in cell and gene therapy
Language(s) - English
Resource type - Journals
ISSN - 2573-8461
DOI - 10.1002/acg2.86
Subject(s) - chimeric antigen receptor , off the shelf , cell therapy , medicine , interim , immunotherapy , business process reengineering , major histocompatibility complex , immunology , t cell , immune system , cell , biology , business , computer science , political science , genetics , marketing , lean manufacturing , software engineering , law
Chimeric antigen receptor (CAR) T cell therapy represents a major breakthrough in the field of immuno‐oncology. Many potential issues are apparent for autologous CAR T cell therapy, such as time for manufacturing and need for interim therapies in progressing patients, wide variations in terms of quality and quantity of T cells, and difficulty to obtain enough cells for redosing. “Off‐the‐shelf” allogeneic CAR T cells premanufactured from third‐party donors may theoretically provide solutions to these different problems. However, allogeneic T cells possess foreign immunological identities that can lead to histocompatibility considerations such as graft‐versus‐host disease and rejection of allogeneic cells. This review outlines the major recent advances for off‐the‐shelf T cell therapies currently in clinical trials or in preclinical development and describes strategies for reengineering or selecting specific T cell immune identities to create safe and efficient immunotherapies for patients.